Nexus loses generic drug approval thanks to contactless FedEx delivery
/cloudfront-us-east-2.images.arcpublishing.com/reuters/D235Z6J2ERM55AY7TEX6XYVIDQ.jpg)
Drugmaker Nexus Pharmaceuticals Inc has lost approval to sell a generic version of Melinta Therapeutics LLC's injectable antibiotic minocin, after a federal judge found that a contactless FedEx delivery at the height of the COVID-19 pandemic did not give Melinta adequate notice of Nexus's application to make the drug.
Monday, October 10, 2022 at 6:55 pm